Assuming the patient has progressed on standard treatments for mCRC including oxaliplatin and irinotecan-containing regimens with the appropriate biologics, I would consider HER2 directed therapy. I generally prefer that to be on clinical trials such as MyPathway or MATCH or similar trials. Outside ...